ClinicalTrials.gg
CompletedNCT06745401Updated Jun 5, 2025

Remote Monitoring of Cancer Patients With Outpatient Treatment

An observational study in Cancer Patients With Outpatient Treatment, sponsored by Persei Vivarium. Completed at 1 site in Spain. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Persei Vivarium · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
34
Sex
All
01

Study summary

This project focuses on studying the use of digital platforms for monitoring, between medical visits, parameters such as toxicities and therapeutic adherence.

The goal of this observational study is to know the degree of usability of the Caaring® digital platform in cancer patients undergoing outpatient oral treatment. This will allow in the future to design comparative studies that demonstrate the advantages of using this application in the management of these patients.

Participants will fill out various questionnaires in the Caaring app related to their symptoms, adherence to treatment, quality of life and physical activity, among others.

02

Conditions studied

  • Cancer Patients With Outpatient Treatment

Keywords

  • Remote patient monitoring
  • Cancer patients
  • outpatient treatment
  • Caaring
  • real-world data
  • DTx
  • patient-reported data
  • Digital Health
  • PROMs
03

In context

Lead sponsor

Persei Vivarium is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer Patients from the Hospital HM Sanchinarro diagnosed who meet the selection criteria and sign the informed consent will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cancer patients with or oncological treatment
  • Cancer patients with oral oncological treatment
  • Patients who are able to complete the study questionnaires
  • Patients who are able to handle the application on a smart mobile phone.
  • is obtained from the patient.

Exclusion criteria

Exclusion Criteria:

  • Patients who will not be able to commit to carrying out the follow-ups or do not have adequate technological skills.
  • Patients with inability to give adequately the .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
34 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Usability of Caaring® for the management of oncology patients in outpatient oral treatment

    Percentage of patients with at least 80% of the data completed in the application, Percentage of patients with 100% of the data completed in the application and Percentage of completion per patient

    Time frame: Day 0 up to 3 months

Secondary outcomes

  1. Degree of completion of data relating to treatment adherence

    The Degree of completion of therapeutic adherence by patients in Caaring application between visits is defined as the ratio between the questionnaires requested and completed.

    Time frame: Weekly up to 3 months

  2. Degree of completion of data related to the toxicity of their treatment

    The Degree of completion of toxicity of their treatments by patients in Caaring application between visits: Percentage of patient participation defined as data completed among requested data; Percentage of patients with at least 80% of the data completed; Percentage of patients with 100% of the data completed and Percentage of patients with at least 80% of the data completed by questionnaire

    Time frame: Weekly up to 3 months

  3. Quality of the care process through impact on the patient's quality of life: WHOQOL

    Changes in patient's quality of life scale WHOQOL (World Health Organization Quality of Life) scores at the end of the study compared to baseline. Values (0-100), a higher score reflects a higher health-related quality of life.

    Time frame: Day 0 and week 12

  4. Quality of the care process through impact on the patient's quality of life: IPAQ

    Changes in International Physical Activity Questionaire (IPAQ) scores at the end of the study compared to baseline. Values (46-100), a higher score reflects a higher Physical Activity

    Time frame: Day 0 and week 12

  5. Patient workload

    Evaluate the Patient workload through the percentage of patients who complete the study correctly by completing all questionnaires

    Time frame: Week 12

07

Study locations

1 site
  • Hospital HM Sanchinarro
    Madrid, 28050, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Mar 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 20, 2024
StartActual
Nov 21, 2024
Primary completionActual
Mar 3, 2025
CompletionActual
Mar 3, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06745401
Lead sponsor
Persei Vivarium
Collaborators
Effice Servicios Para la Investigacion S.L.
Responsible party
Sponsor
First posted
Dec 20, 2024
Start date
Nov 21, 2024
Primary completion
Mar 3, 2025
Completion
Mar 3, 2025
Last update
Jun 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion